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1. Introduction 
Apoptosis is programmed and precisely regulated cell death characterized by 
morphological and biochemical alterations distinct from necrosis (Edinger & Thompson, 
2004). The development of breast cancers, like other processes of carcinogenesis, involves 
uncontrolled cell proliferation and insufficient apoptosis due to either the lack of pro-
apoptotic stimuli in the in vivo environment or the disturbance of cellular apoptotic 
pathways (Brown & Attardi, 2005). Whereas both chemotherapy and radiation caused 
massive apoptotic cell death in the tumor tissues, we are far from conquering the breast 
malignancies until the establishment of targeted pro-apoptotic therapeutic protocols or the 
development of apoptosis-inducing drugs that target the tumor without causing severe 
impairment of the normal organism (Alvarez et al, 2010; Fulda & Debatin, 2006; Motyl et al, 
2006; Muschel et al, 1998). However, thanks to the elucidation of mechanisms underlying 
physiological and pathological apoptosis, studies have been addressed in the development 
of pro-apoptotic strategies targeting the cancer cells, which has provided novel approaches 
to the successful immutherapy of breast cancers (Schlotter et al, 2008). 
2. Unbalanced proliferation and apoptosis in breast cancers 
Cells undergo consistent proliferation and apoptosis during ontogenesis and in maintenance 
of normal morphology and function of multiple organs. These vital behaviors of cells are 
regulated by requisite molecular mechanism so that they are balanced to avoid uncontrolled 
expanding or degeneration of certain tissues (Domingos & Steller, 2007). During 
carcinogenesis, however, these mechanisms were disturbed by or compromised to genetic 
alterations either occurring spontaneously or caused by environmental stress, resulting in 
over-proliferation and resistance to apoptosis (Brown & Attardi, 2005; de Bruin & Medema, 
2008).  
2.1 Apoptotic signaling pathways 
As a process of cell death with hallmarks of morphological abnormalities, e.g. shrunken and 
bubbled cytoplasm, condensed nucleus, fragmented chromatin but intact membrane or 
organelle at the early stage, apoptosis is triggered by extracellular or intracellular stimuli, 
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and results from intracellular signaling thereafter, which ultimately leads to the degradation 
of functional proteins, destroy of cytoskeletons and fragmentation of DNA (Hengartner, 
2000; He et al, 2009). The major initiators, mediators and executioners involved in apoptotic 
signaling have been unraveled, which contribute to a better understanding of carcinogenesis 
in diverse tissues, e.g. the mammary gland (Johnstone et al, 2002).  
Both extrinsic and intrinsic stimuli can initiate apoptotic signaling, which involves the 
activation of downstream mediators in diverse pathways, and converge on the processing of 
cysteine-dependent aspartate-directed proteases, caspases (Hengartner, 2000). Caspases 
exist as proenzymes in cells, and once activated they can cleave various cellular protein 
substrates at concensus amino acid sites, leading the cells to apoptosis (Hengartner, 2000). 
So far two types of caspases have been identified: initiator (apical) caspases, e.g. caspases-2, 
-8, -9 and -10, and effector caspases, e.g. caspases-3, -6 and -7 (Thornberry & Lazebnik, 1998). 
Initiator caspases processed and activated by upstream stimuli could cleave inactive pro-
forms of effector caspases, and effector caspases in turn cleave other protein substrates 
including divergent proteins maintaining normal cell structure, metabolism and 
physiological function, e.g. poly ADP-ribose polymerase (PARP) involved in DNA repair, 
lamin A protein of the cytoskeleton, and the DNA-fragmentation factor DFF45 (Riedl & Shi, 
2004; Timmer & Salvesen, 2007). 
2.1.1 Extrinsic pathway: Death receptor-mediated signaling 
Death receptors are a class of transmembrane receptors that, once engaged by their ligands, 
initiate intracellular signaling resulting in cell death. These receptors belong to a tumor-
necrosis factor receptor (TNFR) superfamily binding to a homotrimeric TNF protein family, 
among which Fas ligand (FasL or CD95L)/Fas have been well-documented (Lavrik, 2005). 
As a type II transmembrane protein, FasL binds and induces the trimerization of Fas, which 
in turn recruits the adaptor molecule Fas-associated death domain (FADD) via interaction 
between their death domains (DD). FADD also contains a death effector domain (DED), 
which aggregates and activates another DED-containing protein, FADD-like interleukin-1ǃ-
converting enzyme (FLICE)/caspase-8. This is followed by a cascade of caspase activation 
and ultimately the cleavage of various protein substrates and apoptosis of the cell (Houston 
& O’Connell, 2004; Wajant, 2002).  
In addition to FasL/Fas, other death receptors and ligands have also been found to play 
vital roles in mediating apoptotic signaling (Houston & O’Connell, 2004; Wajant, 2002). Of 
note are TNF/TNFR and TRAIL/TRAIL-R1, each of which triggers specific signaling 
pathways, thus resulting in apoptosis in a variety of cell types or physiological or 
pathological processes (Baud & Karin, 2001; Gonzalvez &Ashkenazi, 2010). Upon activated 
by TNF, TNFR1 interacts with various death domain-containing proteins, forming a 
complex comprising TRADD, TNF Receptor Associated Factor-2 (TRAF2), cellular inhibitor 
of apoptosis-1 (CIAP1), and the receptor-interacting protein-1 (RIP1). The complex then 
recruits I-kappaB-kinase (IKK) and releases and activates Nuclear Factor-KappaB (NF-κB), 
which actually promotes cell survival (Baud & Karin, 2001; Shen & Pervaiz, 2006). However, 
in a following step, the TRADD-based complex can also dissociate from the receptor and 
bind to FADD, which consequently causes the activation of Caspase-8 and end up with 
apoptosis (Baud & Karin, 2001; Shen & Pervaiz, 2006). The caspase-8 inhibitor FLIP, which is 
a target gene of NF-κB, dictates the outcome of TNF signaling, i.e. whether cells continue to 
survive or undergo apoptosis (Hyer et al, 2006).  
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Growth factors (GFs) represent pro-survival stimuli conteracting the apoptotic signaling. 
After associating with their receptors, GFs activate PI3K (Phosphatidylinositde-3 Kinase) 
and subsequently Akt. Akt suppresses apoptosis via disrupting Bad inhibition of Bcl-2/Bcl-
XL (Duronio, 2008). The protein kinase C (PKC) also inhibits Bad via activation of ribosomal 
S6 kinases (p90RSKs) (Thimmaiah et al, 2010). 
2.1.2 Intrinsic pathway: Role of mitochondrion and endoplasmic reticulum-related 
signaling 
The intrinsic pathway of apoptosis begins when an injury, such as oncogene activation and 
DNA damage, occurs within the cell, or alternatively, cells are in stress, e.g. hypoxia or 
survival factor deprivation (Fulda & Debatin, 2006). The mitochondrion plays a crucial role in 
sensoring and regulating intrinsic signaling pathway, in particular, by providing a platform 
for normal functioning of the Bcl-2 family proteins (Chipuk et al, 2010; Yip & Reed, 2008).  
As a family of proteins containing one or more Bcl-2 homology (BH) domains, which share 
sequence homology and mediate heterodimeric interactions among different members, the 
Bcl-2 family proteins differentially affect mitochondrial outer membrane permeabilization, 
and thus can be divided as anti-apoptotic and pro-apoptotic protein subfamilies (Chipuk et 
al, 2010; Yip & Reed, 2008). The anti-apoptotic proteins, e.g., Bcl-2 and Bcl-XL, are usually 
located on the surface of the mitochondrion and block cell death by preventing the 
activation and homo-oligomerization of the pro-apoptotic Bcl-2 family members. The pro-
apoptotic family members, such as Bax, Bad, Bid and Bak, are often found in the cytosol and 
relocate to the surface of the mitochondria in response to cellular damage or stress (Chipuk 
et al, 2010; Yip & Reed, 2008). Consequently, an interaction between anti-apoptotic proteins 
and excessive pro-apoptotic proteins leads to the formation of pores in the mitochondria 
and the release of cytochrome C and other pro-apoptotic molecules from the intermembrane 
space. The released cytochrome C interacts with Apaf-1 to recruit pro-caspase 9 into a multi-
protein complex called the apoptosome, where caspase-9 is activated. The activated caspase-
9 thus induces the processing of effector caspases, the degradation of diverse substrates of 
caspases and ultimately the morphological and biochemical changes by which apoptosis is 
featured (Scorrano & Korsmeyer, 2003; Inoue et al, 2009).  
Other proteins released from the mitochondria include the apoptosis-inducing factor (AIF), 
second mitochondria-derived activator of caspase (SMAC)/ Diablo, Arts and Omi/high 
temperature requirement protein-A2 (HTRA2). As a ubiquitous mitochondrial 
oxidoreductase, AIF could migrate into the nucleus, bind and cause the destruction of 
genomic DNA, and induce apoptosis in a caspase-independent manner (Modjtahedi, 2006), 
while SMAC/Diablo and HTRA2, once released from the damaged mitochondira, 
counteract the effect of inhibitor of Apoptosis Proteins (IAPs), which normally bind and 
prevent activation of Caspase-3 (Wang & Youle, 2009). The interaction between Bcl-2 family 
members, IAPs, SMAC and Omi/HTRA2 is central to the intrinsic apoptosis pathway 
(Wang & Youle, 2009). 
The tumor suppressor p53 is also a sensor of cellular stress and is a critical activator of the 
intrinsic pathway. As a transcription factor, p53 is phosphorylated and stabilized by DNA 
checkpoint proteins in response to DNA damage, and transcriptionally activates pro-
apoptotic proteins of Bcl-2 family, e.g. Bax and Bid, and other tumor suppressor such as 
PTEN, the outcome of which is cell cycle arrest to allow DNA repair, and apoptosis in cases 
of severe DNA damage (Manfredi, 2010; Robles & Harris, 2001). The mouse double minute-2 
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homolog (MDM2) protein negatively regulates p53 function by mediating the nuclear export 
and ubiquitination of p53 (Manfredi, 2010).  
As an organelle mainly involved in correct protein folding and intracellular trafficking, the 
endoplasmic reticulum (ER) is highly sensitive to stresses that perturb cellular energy levels, 
the redox state or Ca2+ concentration. These ER stresses initiate unfolded protein responses 
(UPR), which promote cell survival and switch to pro-apoptotic signaling when the ER 
stress is prolonged (Rasheva & Domingos, 2009; Szegezdi et al, 2006). ER stress-induced 
apoptosis is a complicated process mediated by a series of specific proteins, in particular, the 
pancreatic ER kinase (PKR)-like ER kinase (PERK), activating transcription factor 6 (ATF6) 
and inositol-requiring enzyme 1 (IRE1) in the initiation phase, the transcription factor 
C/EBP homologous protein (CHOP), growth arrest and DNA damage-inducible gene 34 
(GADD34), Tribbles-related protein 3 (TRB3) and Bcl-2 family members in the commitment 
phase, and ultimately caspases during the execution of apoptosis (Rasheva & Domingos, 
2009; Szegezdi et al, 2006). 
2.2 Alterations of apoptotic signaling in breast cancer cells 
Breast cancer is a malignancy with a wide spectrum of genetic alterations, phenotypic 
heterogeneity, and a variety of contributing etiological factors like age, family history, 
parity, and age of menarche or menopause (McCready et al, 2010). While breast cancers 
share the characteristics, e.g. deregulated proliferation and apoptosis with carcinomas of 
other origins, the molecular mechanisms underlying these characteristics are quite different, 
or even unique for certain processes of breast cancer development or metastasis. To date, 
several molecular markers and related signaling pathways have been revealed to play key 
roles in breast carcinogenesis by causing persistent proliferation and blocked apoptosis of 
breast epithelial cells (McCready et al, 2010). 
2.2.1 Attenuated or blocked signaling in classical apoptotic pathways 
The neoplastic breast epithelial cells have evolved diverse mechanisms to resist apoptosis 
via the extrinsic or intrinsic pathway. The downregulation of Fas or Fas ligand is found in 
numerous breast cancers, and is implicated in prognosis evaluation of patients with breast 
malignancies (Mottolese et al, 2000). Meanwhile, the expression of FasL may also be 
upregulated in breast cancers, which contributes to excessive apoptosis of T cells and thus 
serves as a mechanism of immune escape (Muschen et al, 2000). Signaling by death 
receptors can also be negatively regulated by overexpression of their inhibitors, e.g. the 
FLICE-like inhibitory proteins (FLIP) which dampens caspase-8 activation after recruited to 
the death-inducing signaling complex (DISC) (Rogers et al, 2007). Another inhibitor of death 
receptors, phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes-
15 kDa (PED/PEA-15), has also been implicated in mediating AKT-dependent 
chemoresistance in human breast cancer cells (Eramo et al, 2005). As crucial regulators of 
mitochondrial apoptotic pathway, several Bcl-2 family members have been found aberrantly 
expressed or frequently mutated in breast cancers. For example, overexpression of Bcl-2 or 
Bcl-XL is associated with the development or metastasis of breast carcinomas (Alireza et al, 
2008; Martin et al, 2004). In contrast, the absence or inactivation of the pro-apoptotic Bcl-2 
family members, such as Bax, Bid and Bim is involved in breast carcinogenesis (Sivaprasad 
et al, 2007; Sjöström-Mattson et al, 2009; Whelan et al, 2010). Among the caspase-recruiting 
adaptors, the downregulation of Apaf-1 was found to correlate with the progression of some 
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clinical breast adenocarcinomas (Vinothini et al, 2011). Finally, the polymorphisms and loss 
of function mutations within caspase genes have also been detected in breast cancers 
(Ghavami et al, 2009).  
2.2.2 Reinforced estrogen signaling in breast carcinogenesis  
As a sex hormone, estrogens exert their actions by binding to the intracellular receptors-
estrogen receptors (ER)-ǂ or ER-ǃ. While estrogen/ER regulates growth, differentiation and 
homeostasis of the normal mammary gland, sustained engagement of ER with endogenous 
or exogenous estrogen (E2) is well established to cause breast cancer (Hayashi et al, 2003). In 
fact, ER-positive breast cancers account for 70% of the nearly 200,000 new cases diagnosed 
annually in the USA. Activated ER promotes breast cancer development via three major 
mechanisms: stimulation of cellular proliferation through the receptor-mediated hormonal 
activity, direct genotoxic effects by increasing mutation rates through a cytochrome P450-
mediated metabolic activation, and induction of aneuploidy (J. Russo & I.H. Russo, 2006). 
Estrogen-bound ERs become activated transcription factors via induced dimerization and 
translocation to the nucleus. This is followed by the recognition of the estrogen-responsive 
element (ERE) in the 5’ regulatory sequences of the target genes with the assistance of a 
“pioneer factor”, FoxA1, and consequently the altered expression of the gene via 
recruitment of related transcriptional factors (Yamaguchi, 2007). A growing list of genes 
have proved to be the target of estrogen signaling, among which are cell cycle genes like 
E2F1 and cyclin D1, and those involved in cell survival and oriented differentiation. A 
systemic analysis suggested that estrogen/ER signaling is crucial for the regulation of genes 
involved in an evolutionarily conserved apoptosis pathway (Liu & Chen, 2010). It is also 
hypothesized that estrogen promotes the survival of ER-positive breast cancer cells mainly 
by suppressing the apoptotic machinery or upregulation of the anti-apoptotic molecules, e.g. 
Bcl-2 and Bcl-XL (Gompel et al, 2000; Rana et al, 2010).  
2.2.3 Elevated HER2 expression and signaling in breast carcinogenesis 
Human epidermal growth factor receptor 2 (HER2) is a member of the avian 
erythroblastosis oncogene B (ErbB) protein family with alternative names ErbB2, neu, 
CD340 (cluster of differentiation 340) and p185. As a receptor tyrosine kinase encoded by the 
ERBB2 proto-oncogene, HER2 over-expression has been found in a wide variety of cancers 
(Moasser, 2007). Approximately 30% of breast cancers exhibit an overexpression of HER2 
due to aneuploidy or the amplification of the ERBB2 gene. Transcriptional deregulation 
involving cis-acting element mutation or abnormal activation of transcription factors due to 
dysfunction of tumor suppressors like p53 also contribute to HER2 overexpression 
(Freudenberg et al, 2009; Moasser, 2007). HER2 gene amplification and over-expression are 
frequently detected in high-grade ductal carcinoma in situ (DCIS) and high-grade 
inflammatory breast cancer (IBC), but not in benign breast biopsies such as the terminal duct 
lobular units (TDLUs), suggesting that over-expression of HER2 usually occurs at the 
transition from hyperplasia to DCIS (Freudenberg et al, 2009; Moasser, 2007). HER2 
overexpression in breast cancers correlates with high metastasis capacity, increased disease 
recurrence and worse prognosis, and are therefore routinely examined in breast cancer 
patients for a determination of therapeutic protocol and prediction of the treatment outcome 
(Eccles, 2001).  
www.intechopen.com
 
Targeting New Pathways and Cell Death in Breast Cancer 
 
28
Despite its well-documented association with transformation of normal breast epithelial 
cells and metastasis and poor outcome of breast cancers, the detailed mechanisms 
underlying HER2-mediated signal events and cell behavior are far from being fully 
understood. Nevertheless, it is established that HER2 functions through homodimerization 
and more frequently forming heterodimers with other human epidermal growth factor 
receptors (HERs) (Moasser, 2007; Park et al, 2008). These HERs are commonly activated 
upon binding of a ligand in their extracellular domain, resulting in dimerization of HERs 
and triggering the intrinsic tyrosine kinase activity of the receptors responsible for a mutual 
or monodirectional phosphorylation between the dimerized HERs. The phosphorylated 
tyrosine-containing motif provides a docking station for intracellular signaling molecules 
(Moasser, 2007; Park et al, 2008). Given the existence of several tyrosine phosphorylation 
sites in the intracellular sites, the phosphorylation patterns are unique for a certain HER2 
dimer, and thus trigger downstream signaling different from other dimers. Although none 
of the known HER ligands bind directly to HER2 with high affinity, heregulin, a cytokine 
secreted by the breast stromal cells, can activate HER2 by inducing or stabilizing 
heterodimers with other HER receptors. More importantly, HER2 is the preferred 
heterodimerization partner of other HER receptors like HER3, and strengthens their binding 
to a cognate ligand (Park et al, 2008).  
The HER dimers containg HER2 modulate diverse signaling pathways involved in cell 
proliferation, apoptosis and migration. Adaptor proteins in Ras-MAPK pathway, e.g. Grb2 
and Shc, and the p85 subunit of phosphatidylinositol 3-kinase (PI3K) can bind directly to the 
dimers, leading to prolonged signaling of both pathways (Moasser, 2007; Park et al, 2008). In 
addition to inducing cell over-proliferation via well-defined mechanisms like NF-kB 
activation downstream of PI3K, these signaling events also efficiently inhibit apoptosis via 
negatively regulating tumor suppressors p53 and PTEN, and cell cycle inhibitors p21 
Cip1/WAF1 and p27Kip1 (Park et al, 2008). Whereas the molecular machinery utilized by 
HER2 to promote cell migration and invasion remains unclear, the upregulation of the 
chemokine CXCR4 and thus the stromal cell–derived factor-1 (SDF-1)/CXCR4 axis are 
believed to play a central role in mediating metastasis of HER2-positive cancers (Li et al, 2004).  
2.2.4 Other genetic alterations  
It is now widely accepted that all cancers are attributed to alterations of the genomic 
information or gene expression (Teixeira et al, 2002; Jovanovic et al, 2010). In this regard, 
both germline mutations that increase the risk of carcinogenesis and somatic chromatin 
alterations in specific gene locus have been implicated in the development of breast cancers 
(Teixeira et al, 2002; Jovanovic et al, 2010). Like malignancies in other tissues, breast cancer 
occurs as a result of the activation of oncogenes or dysfunction of a tumor suppressor gene. 
In addition to the well-documented cancer-related genes, e.g. c-Myc, Ras, ATM, p53 and 
PTEN, accumulated data have unraveled a class of genes whose functional abnormalities are 
specifically associated with the development of breast carcinoma (Geyer et al, 2009; 
Prokopcova et al, 2007; Teixeira et al, 2002). This is exemplified by the breast cancer-
susceptibility genes BRCA1 and BRCA2, the mutation of which leads to a lifetime risk of as 
high as 80% of developing breast cancer and accounts for 15% of total breast cancer cases. 
Germline mutations in the BRCA1 and BRCA2 genes result in chromosome instability and 
deficient repair of DNA double-strand breaks by homologous recombination. BRCA-
mediated homologous recombination and DNA repair require their interaction with ataxia 
telangiectasia mutated gene (ATM), RAD51C, BRIP1, Checkpoint kinase 2 (CHEK2) and the 
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partner and localizer of BRCA2 (PALB2), the mutations of which have also been found in 
breast cancer development (Byrnes, 2008; Fulda & Debatin, 2006; Venkitaraman, 2009). 
PIK3CA, an oncogene encoding the PI3K catalytic subunit, exhibits a high frequency of 
gain-of-function mutations in breast cancers, leading to constitutive PI3K/AKT pathway 
activation in breast cancer. PIK3CA mutations have been observed in more than 30% of 
ERǂ-positive breast cancers (Cizkova et al, 2010). 
3. Strategies of targeted apoptosis in breast cancer cells 
Given that resistance to apoptosis is a major causative factor of breast carcinogenesis, 
correction of the deregulated apoptotic process or enforced induction of apoptosis will be 
beneficial in the treatment of breast cancers. However, an ideal apoptosis-based therapeutic 
protocol must be cancer cell-specific in order to avoid impairment of adjacent normal tissues 
or a systemic cytotoxicity of the therapeutics. This could be achieved either by targeted 
delivery of pro-apoptotic molecules in the cancer cells, or by strategies that confer the 
candidate therapeutics apoptosis-inducing activity specifically in the cancer cells (Alvarez et 
al, 2010).  
3.1 Therapeutics that trigger apoptosis in breast cancers 
3.1.1 Apoptosis-inducing chemicals 
Despite a relatively late elucidation of molecular mechanisms of apoptosis, chemical drugs 
or radiation traditionally used for cancer therapy have proved efficient in apoptosis 
induction. DNA-damaging agents like doxorubicin, etoposide, cisplatin or bleomycin may 
induce apoptosis via both extrinsic and intrinsic apoptotic pathways (Fulda & Debatin, 
2006). Treatment of patients with some of these anticancer drugs causes an increase in the 
expression of CD95L/FasL, which stimulates the receptor pathway in an autocrine or 
paracrine manner; conventional chemotherapeutic agents also trigger intrinsic apoptotic 
pathway by eliciting mitochondrial permeabilization (Fulda & Debatin, 2006). In addition, 
detailed mechanism underlying the apoptosis-inducing effect of chemicals may include the 
perturbations of intermediate metabolism, increased expression or activity of p53 or an 
apoptotic mediator, or changes in the ratios of the anti-apoptotic and pro-apoptotic Bcl-2 
family members. For example, paclitaxel treatment causes the accumulation of BH3-only 
Bcl-2 family protein Bim and induces Bim-dependent apoptosis in epithelial tumors (Tan et 
al., 2005); paclitaxel also causes hyperphosphorylation and inactivation of Bcl-2, and 
facilitates the opening of the permeability transition (PT) pore (Ruvolo et al., 2001). 
3.1.2 Apoptosis initiators, mediators and executioners  
The past two decades has witnessed an increasingly clear depiction of the molecular 
machinery of apoptosis, which facilitated the development of strategies aiming at apoptosis 
induction of breast cancer cells (Brown & Attardi, 2005). Theoretically, introduction of any 
active molecule in the irreversible apoptotic pathway is sufficient to trigger apoptosis of 
cancer cells (Waxman & Schwartz, 2003). These active molecules involve extracellular 
cytokines or ligands representing death stimuli, e.g. FasL, tumor necrosis factor-ǂ (TNF-ǂ) 
or the TNF-related apoptosis-inducing ligand (TRAIL), and cellular mediators in the 
apoptotic pathway such as the pro-apoptotic members of Bcl-2 family and adaptors that link 
death signal sensors and caspases. Finally, introduction of apoptotic executioners, in 
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particular, effector caspases in cancer cells, will directly trigger apoptosis independently of 
upstream apoptotic signaling machinery (Ashkenazi, 2008; Fulda & Debatin, 2006).  
While a simple overexpression or accumulation of the apoptotic proteins could commit 
killing of cancer cells, it is also common that a structural modification is needed before 
delivery or ectopic expression in cancer cells due to the following reasons. First, a 
tumoricidal dose of the pro-apoptotic protein, e.g. TNF-ǂ, may also be very closer to a dose 
that causes systemic toxicity. In this case, screening from the mutated or modulated 
counterparts to obtain a lowerly toxic mutant is necessary (Meany et al, 2008). Second, the 
mediators or executioners of apoptosis, such as the Bcl-2 family memebers and caspases, 
exist as inactive zymogen or precursors in the cells, and will not trigger apoptosis unless 
activated (Yip & Reed, 2008). Constitutively active caspases-3 and -6 have been generated by 
removal of the prodomain and rearrangement of the large and small subunits (Srinivasula et 
al, 1998a). Active forms of Bax or Bid can be acquired by deletion of an amino-terminal 
domain, whereas an amino-terminal moiety of AIF is sufficient to trigger the caspase-
independent apoptosis (Yu et al, 2006). Finally, strategies to generate cancer-targeted 
molecules are beneficial to improving the tumoricidal efficacy while alleviating the side 
effect, and therefore add weight to the applicability of the antitumor studies from bench to 
bedside (Alvarez et al, 2010).  
3.1.3 Therapeutics targeting apoptosis inhibitors and growth signals 
During carcinogenesis or acquiring resistance to chemotherapy, many breast epithelial cells 
have developed apoptosis-escaping mechanisms by upregulating a class of apoptosis 
inhibitors (Hyer et al, 2006; Liston et al, 2003). These involve the anti-apoptotic members of 
Bcl-2 family, e.g. Bcl-2 and Bcl-XL, as well as endogenous inhibitors of caspases, e.g. the IAP 
family and c-FLIP proteins (Hyer et al, 2006; Liston et al, 2003). Among the IAPs, both 
survivin and X-linked inhibitor of apoptosis (XIAP) have been targeted in breast cancer 
treatment (Liston et al, 2003). Therefore, antisense oligonucleotides or small interfering 
RNAs (siRNAs) targeted to these inhibitors holds out great promise to counteract these 
inhibitors and possibly restore the apoptotic signaling in these cells (Crnkovic-Mertens, 
2003; Li et al, 2006). The targeting of growth signals that counteract the cellular apoptotic 
machinery was also widely exploited. Of note are the monoclonal antibodies or chemical 
agents which target HER2, vascular endothelial growth factor (VEGF) and the epidermal 
growth factor receptor (EGFR) (Alvarez et al, 2010; Ludwig et al, 2003). Also targeted are the 
heat shock proteins (HSPs), the molecular chaperones required for the stability and function 
of the growth factor signaling and anti-apoptotic proteins (Sánchez-Muñoz et al, 2009).  
3.2 Targeted introduction of apoptosis-inducing proteins 
It has been an inherent challenge to selectively introduce the therapeutics or cytotoxic 
mechanism into the malignant cells in cancer therapy (Alvarez et al, 2010). Theoretically, 
targeted apoptosis induction in breast cancer cells could be achieved via two basic 
approaches. First, pro-apoptotic molecules could be delivered specifically into breast cancer 
cells. Thanks to the characteristic expression of a class of cell surface markers by breast 
cancer cells, antibodies that recognize these markers have been utilized to construct 
apoptosis-eliciting recombinant proteins, or alternatively, to generate targeted delivery 
system for pro-apoptotic genes (Alvarez et al, 2010). Second, the regulatory element, e.g. 
promoter of a gene specifically expressed in breast cancer cells could be used to control the 
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expression of an apoptosis-inducing gene, which results in the tumor-specific expression of 
the gene (Lee, 2009). Despite an overall limited clinical application of these targeted 
strategies, both approaches have proved effective in vitro or in xenograft breast cancer 
models (Alvarez et al, 2010; Lee, 2009).  
In our study, a series of cancer-targeted pro-apoptotic fusion proteins were generated based 
on the active apoptosis mediators or executioners and a single chain antibody, e23sFv, 
which binds HER2 with high affinity (Jia et al, 2003; Xu et al, 2004; Zhao et al, 2004). These 
fusion proteins, designated “immunoapoptotins” after the well documented immunotoxins, 
consist of e23sFv in the amino terminal, a translocation domain and a constitutively active 
apoptotic protein (Pastan et al, 2006). The constitutively active apoptotic proteins were 
obtained by reversing the large and small subunits of caspases-3 or -6, or through 
generating a truncated form of granzyme B, AIF or the pro-apoptotic Bcl-2 family member, 
Bid (Figure 1; Jia et al, 2003; Qiu et al, 2008; Xu et al, 2004; Zhao et al, 2004). A translocation 
domain originating from a protein toxin, Pseudomonas Exotoxin A (PEA), was embedded in 
the fusion protein to mediate a translocation of the apoptotic proteins from an intracellular 
vesicle to the cytosol, which is required for apoptosis execution by a majority of apoptotic 
proteins (Jia et al, 2003; Qiu et al, 2008; Wang et al, 2010; Wang et al, 2007; Xu et al, 2004; 
Zhao et al, 2004). In principle, the single chain antibody mediates the recognition of HER2-
overexpressing breast cancer cells and internalization of the fusion protein via endocytosis. 
In the endosome, the fusion protein undergoes proteolytic processing by a proprotein 
convertase, furin, which is enriched in the intracellular vesicles like lysosome, endosome or 
Golgi apparatus (Wang et al, 2010; Wang et al, 2007). This results in the generation of a 
carboxyl-terminal fragment encompassing the active apoptotic protein, which is released 
into the cytosol and triggers the apoptosis of the cells (Figure 1). Unless processed inside the 
cells, these recombinant proteins are nontoxic due to a steric hindrance of pro-apoptotic 
moiety by the N-terminal antibody and translocation domain (Wang et al, 2010; Wang et al, 
2007). Unlike previously reported tumor killer proteins, such as immunotoxins, the cytotoxic 
activities of the immunoapoptotins are based on human endogenous proteins that kill tumor 
cells in an intrinsic physiologic manner, resulting in relatively weak immunogenicity and 
minor systemic toxicity over repeated treatments (Chen et al, 1997; Jia et al, 2003; Pastan et 
al, 2006).  
These immunoapoptotins could be prepared by engineered bacteria or mammalian cells. 
Alternatively, the construct expressing the immunoapoptotins could be delivered into in 
vivo cells via a retroviral vector or non-viral systems (Jia et al, 2003; Wang, 2010; Xu et al, 
2004). In addition, we also generated lymphocytes that could secrete immunoapoptotins 
after genetic modifications (Jia et al, 2003; Zhao et al, 2004). The apoptosis-inducing 
capacities of the immunoapoptotins were examined in vitro by incubation of the fusion 
proteins with the target cancer cells, coculture of the immunoapoptotin-secreting lymphoma 
Jurkat cells with target cells, or direct transfection of target cells with the construct of an 
amino-terminal signal sequence-containing immunoapototins, which is anticipated to exert 
their tumoricidal effect via an autocrine pattern (Jia et al, 2003; Qiu et al, 2008; Wang et al, 
2010). As a result, the immunoapoptotins selectively induce apoptosis of HER2-positive 
breast cancer SKBr-3 and ovary cancer SKOv-3 cell lines, but not of those that barely express 
HER2. Xenograft tumor models were next generated via subcutaneous injection of the nude 
mice with HER2-positive or -negative breast cancer cells (Jia et al, 2003; Qiu et al, 2008; 
Wang et al, 2010). Intratumoral injection of the immunoapoptotin-producing adenovirus 
resulted in dramatic suppression of tumor growth and significantly prolonged mice 
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survival. In addition, intravenous administration of either the immunoapoptotin-producing 
adenovirus or the lymphocytes that secrete these recombinant proteins also accounted for 
marked tumor suppression in vivo (Jia et al, 2003; Qiu et al, 2008; Wang et al, 2010; Xu et al, 
2004; Zhao et al, 2004). A distribution of immunoapoptotin in the tumor tissue but not other 
major organs was observed, consistent with the detection of redundant apoptosis 
specifically in the xenograft tumors (Jia et al, 2003; Wang et al, 2010; Xu et al, 2004; Zhao et 
al, 2004). These results indicate that the immunoapoptotins, which combines the properties 
of a tumor-specific antibody with the potent tumoricidal activity of apoptotic mediators or 
executioners, may provide novel approaches to immunotherapy or gene therapy of HER2-
positive breast cancers. The genetically modified somatic cells, especially lymphocytes, are 
expected to suppress primary tumors and micrometastases, owing to continuous secretion 
of the fusion proteins and their diffusion through blood and lymph fluid. These modified 
cells remain viable because they are HER2-negative and the immunoapoptotins are directed 
to the lumen of the endoplasmic reticulum and secreted co-translationally (Jia et al, 2003; Xu 
et al, 2004; Zhao et al, 2004).  
 
 
The “immunoapoptotin” fusion proteins consist of a single-chain antibody (scFv), a translocation 
domain (TD) and a constitutively active apoptosis mediator/executioner (AME). The antibody 
recognizes a distinguished surface marker (e.g. HER2) of breast cancer cells, and internalizes via 
endocytosis; the translocation domain mediates the processing of the fusion protein in the endosome or 
lysosome by furin to release into the cyotsol a C-terminal moiety; the released moiety containing the 
AME triggers apoptosis of the cell independently of the endogenous upstream apoptotic machinery.  
Fig. 1. Immunoapoptotins specifically induce apoptosis of breast cancer cells. 
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Another constituent in the immunoapoptotins that need to be addressed is the translocation 
domain, which is exogenous to human and thus has potentials to elicit immunological 
responses, resulting in either systemic toxicity or neutralization of the killer protein (Wang 
et al, 2010; Wang et al, 2007). To ameliorate the primary structure of the killer protein, we 
generated truncated variants of PEA or diphtheria toxin (DT) translocation domains to 
identify the minimal sequence required for furin processing and translocation (Wang et al, 
2010; Wang et al, 2007). Consequently, we found that peptides encompassing the 273rd to 
282nd amino acids of PEA (TRHRQPRGWE), or 187th to 196th amino acids of DT 
(AGNRVRRSVG) are furin-sensitive sequences, and immunoapoptotins based on these 
translocation sequences exhibited relatively low systemic toxicity while maintaining potent 
pro-apoptotic activities when applied to HER2-positive cancers (Wang et al, 2010; Wang et 
al, 2007). Considering that cancer specific antigens other than HER2 can also be targeted by 
an antibody, our immunoapoptotin strategy would have a versatile applicability in the 
treatment of breast cancers with distinguished cell surface biomarkers.  
Estrogen receptor overexpression and estrogen-dependence are found in a majority of breast 
cancer cases (Ghazoui et al, 2011). A class of selective estrogen receptor modulators 
(SERMs), as represented by tamoxifen (TAM), have been used for targeted therapy of these 
breast cancers with encouraging outcomes at least partially via reversing the anti-apoptotic 
effect of estrogen receptor signaling (Jordan & O'Malley, 2007). Unfortunately, use of SERMs 
is associated with de novo and acquired resistance and some undesirable side effects (Jordan 
& O'Malley, 2007). In contrast, a targeted introduction or activation of a cellular apoptosis 
executioner will elicit irreversible cell death without inducing drug resistance (Waxman & 
Schwartz, 2003). According to the well-documented “induced proximity model”, the 
activation of the initiators occurs only when they are recruited by upstream oligomerization 
inducers, which bring the procaspases into close proximity and thus allow intramolecular 
processing (Shi, 2004). This model has been applied in developing pro-apoptotic strategies 
in cancer treatment based on the oligomerization capacity of either mouse IgG Fc portion or 
the tandem FK506-binding domain (FKBP) plus its dimeric ligand FK1012 (Muzio et al, 
1998; Shi, 2004; Srinivasula et al, 1998b). In a study focusing on ER-positive breast cancer 
treatment, we generated a fusion gene encoding the chimeric protein of caspase-8 and the 
ligand-binding domain (LBD) of ERǂ and introduced the gene into breast cancer cell lines 
(Zhao et al, 2011). Upon administration of estrogen, the fusion protein will be induced to 
form a dimer, which triggers the activation of caspase-8 and apoptosis (Tamrazi et al, 2002; 
Shi, 2004). Indeed, incubation of estradiol with the chimeric gene-modified breast cancer 
cells induced a rapid dimerization of the chimeric protein, which in turn caused the 
activation of caspase-8 within the chimeric protein and leads to apoptosis of the modified 
cells (Zhao et al, 2011). Estradiol also significantly impaired the development of the 
xenograft breast cancers derived from the chimeric gene-modified SKBr-3 cells, and 
inhibited the growth of in vivo tumors originating from MCF-7 cells when administered in 
combination with the chimeric gene recombinant adenovirus (Zhao et al, 2011).  
Unlike previously reported artificial caspase recruitment models, our study employed the 
receptor of endogenous estrogenic hormones, which otherwise promote the growth of 
breast cancer cells, to trigger the apoptotic signaling in breast cancers, thus switching the 
estrogenic hormones from potential mitogens to apoptosis inducers in breast cancers (Shi, 
2004; Zhao et al, 2011). Therefore, the caspase-8 and estrogen receptor-based chimeric 
protein has implications in developing novel therapeutics of estrogen-dependent and -
independent breast cancers. Despite the effectiveness of the chimeric protein, optimization 
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of this suicidal system using an accurate dimerization-related domain of ERǂ is necessary 
for preventing inappropriate autoactivation of chimeric caspase-8; given that the estrogen 
antagonist, tamoxifen, is also found to induce the formation of ER dimers in a much lower 
efficiency, it remains elusive whether tamoxifen in place of estradiol could trigger 
dimerization and activation of caspase-8 conjugated to the ER ligand-binding domain 
(Tamrazi et al, 2002; Zhao et al, 2011).  
In addition to the generation of fusion/chimeric proteins, the pro-apoptotic gene regulatory 
elements, as well as the gene construct carriers, either non-viral or viral particles, have also 
been modified to target breast cancers. The antibody-drug conjugate, Trastuzumab-DM1 is 
currently in a late clinical trial for treatment of HER2-positive breast cancers (Alley et al, 
2010; Senter, 2009). Breast cancer-targeted delivery systems are also constructed by 
modifying the envelop of viral particles, liposomes or other nanomaterials with tumor cell-
binding phage peptides, or with ligands or antibodies that recognize HER2, E-selectin, 
transferrin or erythropoietin-producing hepatocellular receptor tyrosine kinase receptor class 
A2 (EphA2) (Alvarez et al, 2010; Mann et al, 2010; Normanno et al, 2009; Sarkar et al, 2005; 
Tandon et al, 2011). Tumor-specific regulatory elements, such as promoters of human 
telomerase reverse transcriptase (hTERT), survivin, Muc1 and the homologous recombination-
related protein Rad51, as well as the hypoxia-responsive elements (HRE) have been employed 
in the regulation of pro-apoptotic genes like Bax and truncated Bid in the development of 
breast cancer-targeted therapeutic strategies (Lee, 2009; Kazhdan et al, 2006; Hine et al, 2008).  
3.3 Selective blockade of anti-apoptotic signaling 
It is widely accepted that intracellular apoptosis-inhibitory mechanisms account for a rapid 
progression and chemotherapy resistance of a variety of breast cancers. Therefore, targeted 
restoration of the apoptotic signaling by suppression of the anti-apoptotic factors helps 
reverse the malignant phenotype of breast cancers (Fulda & Debatin, 2006; Waxman & 
Schwartz, 2003). This could be achieved in the post-transcriptional level by targeted siRNA 
or in the post-translational level via targeted degradation of the anti-apoptotic proteins 
(Fulda & Debatin, 2006; Waxman & Schwartz, 2003). Considering that the short hairpin 
RNA (shRNA) expression is commonly driven by an RNA polymerase III promoter, which 
somehow excludes a modification of the promoter using a tumor-specific elements, specific 
delivery of siRNAs instead of selective expression of the shRNAs in neoplastic cells would 
be appropriate to targeting breast cancer cells (Couto and High, 2010; Wen et al, 2008). 
Again, the antibodies or ligands that recognize breast cancer cells are utilized in these 
targeted delivery systems (Couto and High, 2010; Wen et al, 2008). In one of our studies, a 
subset of siRNA delivery systems were generated by fusing a tumor-targeting antibody 
with the nucleic acid-binding peptide derived from the arginine-rich protein, protamine. 
The targeted delivery of the synthesized siRNA or shRNA-expressing cassette in cells 
expressing the corresponding antigen was corroborated in in vivo models (Wen et al, 2008).  
The protein ubiquitination process governs the degradation of unfavored endogenous 
proteins in the cells. In an attempt to trigger targeted degradation of the breast cancer-
related proteins, Li et al generated a series of chimeric molecules in which the Src homology 
2 (SH2) domain of the ubiquitin ligase Cbl was replaced with that from growth factor 
receptor binding protein 2 (Grb2), Grb7, p85 or Src (Li et al, 2007). These chimeric proteins 
could interact with HER2 and accelerate the degradation of this oncoprotein, suggesting a 
novel approach to the targeted therapy of HER2-overexpressing cancers (Li et al, 2007). 
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4. Targeted apoptosis in clinical treatment of breast cancers 
The development of targeted pro-apoptotic strategies in laboratory studies on breast cancer 
treatment is in parallel with the emerging of novel targeted agents for clinical breast cancer 
therapy (Fulda & Debatin, 2006; Waxman & Schwartz, 2003). As aforementioned, 
monoclonal antibodies or small molecule inhibitors targeting HER2 
(Herceptin/trastuzumab), EGFR (Gefitinib/Iressa) and VEGF (Avastin/Bevacizumab) have 
found their clinical applications in the war against breast cancers (Schlotter et al, 2008). In 
particular, as a well-documented adjuvant drug for metastatic breast cancer therapy, 
Herceptin has provided startling benefits to patients by reducing suffering and mortality of 
breast cancers, although frequent resistance development and cardiovascular toxicity have 
limited its repeated administration (Paik et al, 2008). In clinical trials of breast cancers, the 
death receptor ligands recombinant TNF-ǂ and TRAIL have exhibited notable apoptosis-
inducing potentials (Gonzalvez &Ashkenazi, 2010; Li et al, 2010). Intriguingly, TRAIL has 
displayed minimal adverse effects on normal tissues and the most striking therapeutic 
benefits in patients with HER2, ER and progesterone receptor (PR) triple-negative breast 
cancers (Oakman et al, 2010; 19: 312). Targeted expression of TRAIL under the control of a 
radiation-inducible RecA promoter delivered by Salmonella typhimurium significantly 
improved the survival of mice bearing breast cancers (Ganai et al, 2009).  
Small RNAs or chemicals targeting the anti-apoptotic genes are also on their way towards 
the prescription for breast cancer patients. However, as a pioneering anticancer nucleic acid 
drug, G3139- the antisense oligonucleotide targeting Bcl-2 showed limited therapeutic 
efficacy when combined with doxorubicin and docetaxel in phage I/II studies on breast 
cancers (Moulder et al, 2008). Inhibitors to poly(ADP-ribose) polymerase-1 (PARP-1), a well-
defined substrate of caspase-3, have showed single agent activity in treatment of breast 
cancers in a phase I trial, and conferred therapeutic benefits in combination with 
chemotherapy in triple-negative breast cancers without an increase in normal tissue toxicity 
in a phase II clinical trial. (Drew & Plummer, 2010). 
5. Conclusion and perspective 
Accumulating evidence on breast malignancies has supported that insufficient apoptosis 
contributes crucially to the occurrence and progression of breast cancers, and apoptosis 
resistance accounts for failure of traditional anticancer therapy on a majority of clinical 
breast cancers (Brown & Attardi, 2005; Evan & Vousden, 2001). In recent years, an extensive 
understanding of the canonical apoptosis signaling mechanisms has allowed the 
development of novel approaches to reversing or compensating for the apoptosis deficiency 
of cancer cells, either by introduction of a pro-apoptotic molecule or via blockade of the anti-
apoptotic signals in breast cancers (Fulda & Debatin, 2006; Waxman & Schwartz, 2003). 
Given the distinguished expression of the definitive tumor-specific antigens (TSA) in breast 
carcinomas, strategies targeting these cells could be developed based on specific recognition 
mediated by antigen/antibody or ligand/receptor binding or on a selective expression of 
the therapeutic genes under the control of the TSA regulatory elements (Rakha et al, 2010; 
Schlotter et al, 2009). Despite a successful clinical application of the targeted drugs, e.g. 
antibodies or chemical reagents to trigger apoptosis in numerous breast cancer cases, 
modifications to these drugs are probably necessary for two purposes (Alley et al, 2010; 
Fulda & Debatin, 2006). First, combination of the therapeutic antibodies or chemicals with 
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other potent cytotoxic mechanisms will improve their apoptosis-inducing efficacy in breast 
cancers. Second, additional approaches to achieving a “genuine” breast cancer targeting in 
drug delivery or gene expression facilitate reducing a systemic cytotoxicity or other adverse 
effects on patients (Alley et al, 2010; Lee, 2009). Nevertheless, the ongoing studies aiming at 
targeted apoptosis induction in breast cancers have opened new avenues to successful 
breast cancer immunotherapy.  
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